Oruka Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
Oruka Therapeutics, Inc. (ORKA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $7.00 thousand as of 2023-12-31, per its 10-K filed 2024-02-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2024-02-01
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $7.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $6.00K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $196.00K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $22.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2023-12-31 | $7.00K 10-K · filed 2024-02-01 |
| 2022-12-31 | $6.00K 10-K · filed 2024-02-01 |
| 2021-12-31 | $196.00K 10-K · filed 2023-02-24 |
| 2020-12-31 | $22.00K 10-K · filed 2022-03-14 |
| 2019-12-31 | $16.00K 10-K · filed 2021-03-18 |
| 2018-12-31 | $20.00K 10-K · filed 2020-02-18 |
| 2017-12-31 | $168.00K 10-K · filed 2019-02-27 |
| 2016-12-31 | $35.00K 10-K · filed 2018-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |